Generic Name and Formulations:
Temazepam 7.5mg, 15mg, 22.5mg, 30mg; caps.
Indications for RESTORIL:
Short-term (7–10 days) treatment of insomnia.
Use lowest effective dose. Usual dose: 7.5mg–30mg at bedtime. Elderly or debilitated: initially 7.5mg. Max 1 month/℞.
<18yrs: not established.
Risks from concomitant use with opioids.
Risks from concomitant use with opioids (see Interactions). Suicidal tendencies. Depression. Pulmonary, renal, or hepatic impairment. Drug or alcohol abuse. Reevaluate if used ≥2 weeks. Sleep disturbances after stopping drug. Avoid abrupt cessation after prolonged use. Elderly. Nursing mothers.
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Additive CNS depressant effects with alcohol or other CNS depressants.
Drowsiness, headache, fatigue, nervousness, lethargy, dizziness, hangover, confusion, weakness, paradoxical excitement, euphoria; sleep-driving and other complex behaviors (eg, preparing/eating food), anaphylaxis, angioedema.
Caps 7.5mg—30, 100; 22.5mg—30; 15mg, 30mg—100
Renal and Urology News Articles
- Clinicians Somewhat Favor Shared Decision-Making in Older mCRPC Patients
- Higher Push-Up Capacity Linked to Lower Incidence of CVD Events
- Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer
- Dialysis and Transplant Patients at Increased Risk for Cancer Death
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)